Document is current
Any future updates will be listed below
-
Authors
Zhang, Chao
Guo, Qiang
Chen, Lifeng
Wu, Zheming
Yan, Xiao-Jian
Zou, Chengyang
Zhang, Qiuxue
Tan, Jiahong
Fang, Tian
Rao, Qunxian
Li, Yang
Shen, Shizhen
Deng, Min https://orcid.org/0000-0003-1987-9775
Wang, Liewei
Gao, Huanyao
Yu, Jia https://orcid.org/0000-0001-8342-5423
Li, Hu https://orcid.org/0000-0001-5957-5472
Zhang, Cheng
Nowsheen, Somaira
Kloeber, Jake https://orcid.org/0000-0002-6646-564X
Zhao, Fei
Yin, Ping
Teng, Chunbo
Lin, Zhongqiu
Song, Kun https://orcid.org/0000-0001-6110-2770
Yao, Shuzhong
Yao, Liangqing
Wu, Lingying
Zhang, Yong
Cheng, Xiaodong
Gao, Qinglei https://orcid.org/0000-0002-9448-3423
Yuan, Jian
Lou, Zhenkun https://orcid.org/0000-0003-1938-3091
Zhang, Jin-San
- License Information
-
More Information
Article History
Received: 1 October 2022
Revised: 4 February 2023
Accepted: 27 February 2023
First Online: 10 May 2023
Competing interests
: A patent is pending for J-S.Z., C.Z., and Q.G. Patent applicant: J-S.Z.; the name of inventors: Zhang Jin-San, Zhang Chao, Guo Qiang; application number: 2021102042329; status of application: under application; specific aspect of manuscript covered in patent application: the gene panel predicting patients’ response to PARP inhibitor and cisplatin.
: The OV organoids were derived from surgery samples or ascites of ovarian cancer patients at Yixing People’s Hospital, Yixing, China. The study received approval from the Ethical Committee of Yixing People’s Hospital (Trial No. 060, 2020). The observational study of platinum-sensitive relapsed ovarian cancer patients who received PARP inhibitor therapy has been approved by the Ethical Review Committee of different hospitals (ethical batch number: 2021S031; 20180196).
